{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:20:20Z","timestamp":1791231620219,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T00:00:00Z","timestamp":1667433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T00:00:00Z","timestamp":1667433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s00520-022-07401-y","type":"journal-article","created":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T06:04:38Z","timestamp":1667455478000},"page":"10471-10482","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Management of adverse events related to first-generation tyrosine receptor kinase inhibitors in adults: a narrative review"],"prefix":"10.1007","volume":"30","author":[{"given":"Christine","family":"Martineau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Kim","family":"Turcotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00e9mie","family":"Otis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Provost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovic","family":"Themens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Pascale","family":"Guay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Letarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7938-0944","authenticated-orcid":false,"given":"Jean-Philippe","family":"Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,3]]},"reference":[{"key":"7401_CR1","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","volume":"15","author":"E Cocco","year":"2018","unstructured":"Cocco E, Scaltriti M, Drilon A et al (2018) NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol 15:731\u2013747","journal-title":"Nat Rev Clin Oncol"},{"key":"7401_CR2","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/j.annonc.2020.08.2232","volume":"11","author":"GD Demetri","year":"2020","unstructured":"Demetri GD, Antonescu CR, Bjerkehagen B et al (2020) Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network. Ann Oncol 11:1506\u20131517","journal-title":"Ann Oncol"},{"key":"7401_CR3","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1080\/13543776.2020.1737011","volume":"5","author":"JJ Bailey","year":"2020","unstructured":"Bailey JJ, Jaworski C, Tung D et al (2020) Tropomyosin receptor kinase inhibitors: an updated patent review for 2016\u20132019. Expert Opin Ther Pat 5:325\u2013339","journal-title":"Expert Opin Ther Pat"},{"key":"7401_CR4","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s11523-018-0590-1","volume":"13","author":"S Kummar","year":"2018","unstructured":"Kummar S, Lassen UN (2018) TRK inhibition: a new tumor-agnostic treatment strategy. Target Oncol 13:545\u2013556","journal-title":"Target Oncol"},{"issue":"Suppl 2","key":"7401_CR5","first-page":"1","volume":"4","author":"U Lassen","year":"2019","unstructured":"Lassen U (2019) How I treat NTRK gene fusion-positive cancers. ESMO Open 4(Suppl 2):1\u20133","journal-title":"ESMO Open"},{"key":"7401_CR6","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3390\/curroncol28010038","volume":"28","author":"S Perreault","year":"2021","unstructured":"Perreault S, Chami R, Deyell RJ et al (2021) Canadian consensus for biomarker testing and treatment of TRK fusion cancer in pediatric patients. Curr Oncol 28:346\u2013366","journal-title":"Curr Oncol"},{"key":"7401_CR7","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3390\/curroncol28010053","volume":"28","author":"DG Bebb","year":"2021","unstructured":"Bebb DG, Banerji S, Blais N et al (2021) Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults. Curr Oncol 28:523\u2013548","journal-title":"Curr Oncol"},{"key":"7401_CR8","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.annonc.2020.05.006","volume":"9","author":"D Liu","year":"2020","unstructured":"Liu D, Flory J, Lin A et al (2020) Characterization of on-target adverse events caused by TRK inhibitor therapy. Ann Oncol 9:1207\u20131215","journal-title":"Ann Oncol"},{"key":"7401_CR9","first-page":"39897","volume":"20","author":"JSJ Lim","year":"2020","unstructured":"Lim JSJ, Tan DSP (2020) TRK inhibitors-managing on-target toxicities. Ann Oncol 20:39897\u201339905","journal-title":"Ann Oncol"},{"key":"7401_CR10","unstructured":"OnTarget. Available at https:\/\/ontargetonco.com\/. Accessed May 13, 2021"},{"key":"7401_CR11","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","volume":"21","author":"RC Doebele","year":"2020","unstructured":"Doebele RC, Drilon A, Paz-Ares L et al (2020) Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1\u20132 trials. Lancet Oncol 21:271\u2013282","journal-title":"Lancet Oncol"},{"key":"7401_CR12","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/NEJMoa1714448","volume":"378","author":"A Drilon","year":"2018","unstructured":"Drilon A, Laetsch TW, Kummar S et al (2018) Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 378:731\u2013739","journal-title":"N Engl J Med"},{"key":"7401_CR13","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Available at https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/Archive\/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf. Accessed May 13, 2021"},{"issue":"suppl 8","key":"7401_CR14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/annonc\/mdz282","volume":"20","author":"A Drilon","year":"2019","unstructured":"Drilon A (2019) TRK inhibitors in TRK fusion-positive cancers. Ann Oncol 20(suppl 8):23\u201330","journal-title":"Ann Oncol"},{"key":"7401_CR15","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1007\/s00520-010-0902-1","volume":"18","author":"AJ Hovan","year":"2010","unstructured":"Hovan AJ, Williams PM, Stevenson-Moore P et al (2010) A systematic review of dysgeusia induced by cancer therapies. Support Care Cancer 18:1081\u20131087","journal-title":"Support Care Cancer"},{"key":"7401_CR16","unstructured":"Hoffman-La Roche Limited. Product monograph including patient medication information: Rozlytrek. Available at https:\/\/www.rochecanada.com\/content\/dam\/rochexx\/roche-ca\/products\/ConsumerInformation\/MonographsandPublicAdvisories\/Rozlytrek\/Rozlytrek_PM_E.pdf. Accessed May 13, 2021"},{"key":"7401_CR17","unstructured":"U.S. Food and Drug Administration. Prescribing information: Rozlytrek. Available at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/212725s000lbl.pdf. Accessed May 13, 2021"},{"key":"7401_CR18","unstructured":"Bayer Inc. Product monograph including patient medication information: Vitrakvi. Available at https:\/\/omr.bayer.ca\/omr\/online\/vitrakvi-pm-en.pdf. Accessed May 13, 2021"},{"key":"7401_CR19","unstructured":"U.S. Food and Drug Administration. Prescribing information: Vitrakvi. Available at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/211710s000lbl.pdf. Accessed May 13, 2021"},{"key":"7401_CR20","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1200\/JCO.20.01399","volume":"38","author":"CL Loprinzi","year":"2020","unstructured":"Loprinzi CL, Lacchetti C, Bleeker J et al (2020) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. J Clin Oncol 38:3325\u20133345","journal-title":"J Clin Oncol"},{"key":"7401_CR21","doi-asserted-by":"crossref","unstructured":"Timmins HC, Mizrahi D, Li T et al (2021) Metabolic and lifestyle risk factors for chemotherapy-induced peripheral neuropathy in taxane and platinum-treated patients: a systematic review. J Cancer Surviv. Abstract s11764\u2013021\u201300988-x","DOI":"10.1007\/s11764-021-00988-x"},{"key":"7401_CR22","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2217\/fon-2016-0296","volume":"13","author":"K Fife","year":"2017","unstructured":"Fife K, Herd R, Lalondrelle S et al (2017) Managing adverse events associated with vismodegib in the treatment of basal cell carcinoma. Future Oncol 13:175\u2013184","journal-title":"Future Oncol"},{"key":"7401_CR23","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1634\/theoncologist.2015-0268","volume":"21","author":"KN Moore","year":"2016","unstructured":"Moore KN, Monk BJ (2016) Patient counseling and management of symptoms during olaparib therapy for recurrent ovarian cancer. Oncologist 21:954\u2013963","journal-title":"Oncologist"},{"key":"7401_CR24","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.esmoop.2021.100113","volume":"6","author":"L Paz-Ares","year":"2021","unstructured":"Paz-Ares L, Barlesi F, Siena S et al (2021) Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours. ESMO Open 6:100\u2013113","journal-title":"ESMO Open"},{"key":"7401_CR25","doi-asserted-by":"publisher","unstructured":"Hesketh PJ, Kris MG, Basch E, et al (2020) Antiemetics: ASCO Guideline Update. J Clin Oncol 38(24):2782\u20132797.\u00a0https:\/\/doi.org\/10.1200\/JCO.20.01296","DOI":"10.1200\/JCO.20.01296"},{"key":"7401_CR26","unstructured":"U.S. Food and Drug Administration. Prescribing information: Akynzeo. Available at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210493s000lbl.pdf. Accessed May 28, 2021"},{"issue":"Suppl 4","key":"7401_CR27","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1093\/annonc\/mdy145","volume":"29","author":"P Bossi","year":"2018","unstructured":"Bossi P, Antonuzzo A, Cherny NI et al (2018) Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 29(Suppl 4):126\u2013142","journal-title":"Ann Oncol"},{"key":"7401_CR28","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1161\/CIR.0000000000000509","volume":"136","author":"CW Yancy","year":"2017","unstructured":"Yancy CW, Jessup M, Bozkurt B et al (2017) 2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines and the Heart Failure Society of America. Circulation 136:137\u2013161","journal-title":"Circulation"},{"key":"7401_CR29","unstructured":"European Society for Medical Oncology. ESMO Clinical Practice Guidelines: supportive and palliative care. Available at https:\/\/www.esmo.org\/guidelines\/supportive-and-palliative-care. Accessed June 11, 2021"},{"key":"7401_CR30","unstructured":"Harvard T.H. Chan School of Public Health. Obesity prevention source. Available at https:\/\/www.hsph.harvard.edu\/obesity-prevention-source\/obesity-causes\/diet-and-weight\/. Accessed June 11, 2021"},{"key":"7401_CR31","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1161\/CIR.0000000000000973","volume":"143","author":"TM Powell-Wiley","year":"2021","unstructured":"Powell-Wiley TM, Poirier P, Burke LE et al (2021) Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 143:984\u20131010","journal-title":"Circulation"},{"key":"7401_CR32","unstructured":"American Society of Clinical Oncology (ASCO). Joint pain. Available at https:\/\/www.cancer.net\/coping-with-cancer\/physical-emotional-and-social-effects-cancer\/managing-physical-side-effects\/joint-pain. Accessed June 8, 2021"},{"key":"7401_CR33","unstructured":"BreastCancer.org. Muscle Pain (Myalgia). Available at https:\/\/www.breastcancer.org\/treatment\/side_effects\/muscle_pain. Accessed June 8, 2021"},{"key":"7401_CR34","doi-asserted-by":"crossref","unstructured":"ESMO (2018) Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 29 (Suppl 4): 126\u2013142.","DOI":"10.1093\/annonc\/mdy145"},{"key":"7401_CR35","unstructured":"BC Cancer Agency. Symptom management guidelines: pain. Available at http:\/\/www.bccancer.bc.ca\/nursing-site\/Documents\/13.%20Pain.pdf. Accessed June 4, 2021"},{"key":"7401_CR36","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.annonc.2020.07.003","volume":"31","author":"B Jordan","year":"2020","unstructured":"Jordan B, Margulies A, Cardoso F et al (2020) Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up. Ann Oncol 31:1306\u20131319","journal-title":"Ann Oncol"},{"key":"7401_CR37","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/14737140.2020.1747439","volume":"20","author":"A Sartore-Bianchi","year":"2020","unstructured":"Sartore-Bianchi A, Pizzutilo EG, Marrapese G et al (2020) Entrectinib for the treatment of metastatic NSCLC: safety and efficacy. Expert Rev Anticancer Ther 20:333\u2013341","journal-title":"Expert Rev Anticancer Ther"},{"key":"7401_CR38","unstructured":"BC Cancer. Problems with balance and coordination. Available at http:\/\/www.bccancer.bc.ca\/managing-symptoms-site\/Documents\/Balance-and-Coordination.pdf. Accessed May 19, 2021"},{"key":"7401_CR39","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1080\/17512433.2019.1661775","volume":"12","author":"N Federman","year":"2019","unstructured":"Federman N, McDermott R (2019) Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer. Expert Rev Clin Pharmacol 12:931\u2013939","journal-title":"Expert Rev Clin Pharmacol"},{"key":"7401_CR40","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1634\/theoncologist.2016-0186","volume":"21","author":"ME Lacouture","year":"2016","unstructured":"Lacouture ME, Dr\u00e9no B, Ascierto PA et al (2016) Characterization and management of hedgehog pathway inhibitor-related adverse events in patients with advanced basal cell carcinoma. Oncologist 21:1218\u20131229","journal-title":"Oncologist"},{"key":"7401_CR41","unstructured":"BC Cancer Agency. Nutritional guidelines for symptom management: taste changes. Available at http:\/\/www.bccancer.bc.ca\/nutrition-site\/Documents\/Symptom%20management%20guidelines\/TasteChanges.pdf. Accessed May 26, 2021"},{"key":"7401_CR42","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40265-018-1044-x","volume":"79","author":"LJ Scott","year":"2019","unstructured":"Scott LJ (2019) Larotrectinib: first global approval. Drugs 79:201\u2013206","journal-title":"Drugs"},{"key":"7401_CR43","unstructured":"National Comprehensive Cancer Network. NCCN guidelines \u2013 supportive care. Available at nccn.org\/guidelines\/category_3. Accessed June 11, 2021"},{"key":"7401_CR44","unstructured":"U.S. Food and Drug Administration. Prescribing information: Varubi. Available at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/206500s000lbl.pdf. Accessed May 28, 2021"},{"key":"7401_CR45","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S1470-2045(14)70006-3","volume":"15","author":"J Andreyev","year":"2014","unstructured":"Andreyev J, Ross P, Donnellan C et al (2014) Guidance on the management of diarrhoea during cancer chemotherapy. Lancet Oncol 15:447\u2013460","journal-title":"Lancet Oncol"},{"key":"7401_CR46","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1177\/1758834009355164","volume":"2","author":"A Stein","year":"2010","unstructured":"Stein A, Voigt W, Jordan K (2010) Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol 2:51\u201363","journal-title":"Ther Adv Med Oncol"},{"key":"7401_CR47","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/annonc\/mdy539","volume":"30","author":"DS Hong","year":"2019","unstructured":"Hong DS, Bauer TM, Lee JJ et al (2019) Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study. Ann Oncol 30:325\u2013331","journal-title":"Ann Oncol"},{"key":"7401_CR48","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","volume":"21","author":"DS Hong","year":"2020","unstructured":"Hong DS, DuBois SG, Kummar S et al (2020) Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase \u00bd clinical trials. Lancet Oncol 21:531\u2013540","journal-title":"Lancet Oncol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-07401-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-022-07401-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-07401-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T13:26:24Z","timestamp":1669901184000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-022-07401-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,3]]},"references-count":48,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["7401"],"URL":"https:\/\/doi.org\/10.1007\/s00520-022-07401-y","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,3]]},"assertion":[{"value":"17 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}